6 月 21 日，美国时间，先为达生物将在美国糖尿病协会（ADA）年会上以口头报告形式，公布其 cAMP 偏向性 GLP-1 类似物埃诺格鲁肽 （Ecnoglutide，原名伊诺格鲁肽）注射液在超重或肥胖成人中开展的 III 期 SLIMMER 临床试验数据。 据公开摘要显示，这项为期 48 周的 III 期临床研究采用双盲、随机、安慰剂对照设计，在中国 36 家医疗机构展开，共招募 664 名超重或肥胖 受试者，按每周一次注射 1.2、1.8 或 2.4 毫克剂量的埃诺格鲁肽或安慰剂进行治疗。 整理 | GLP1减重宝典内容团队 研究的主要评估指标为第 40 周时体重相较基线的变化百分比，以及体重减轻 ≥5% 的受试者比例。 根据 Insight 数据库披露的结果，受试者初始平均体重为 91.3 千克，平均 BMI 为 32.5 kg/m²。 至第 48 周时，埃诺格鲁肽各剂量组平均体重下降幅度为 9.9% 至 15.4%，显著优于安慰剂组（下降 0.3%，P<0.0001）。在使用埃诺格鲁肽的 受试者中，77.7% 至 92.8% 体重减少至少 5%，51.2% 至 79.6% 减重超过 10%，另有 6 ...

Core Viewpoint - The article emphasizes the growing obesity problem in China, highlighting the need for a national strategy to address obesity as a significant public health challenge, which is crucial for advancing the "Healthy China" initiative [4][5]. Group 1: Current Situation and Challenges - Over half of the adult population in China is classified as overweight or obese, with the growth rate of obese individuals surpassing that of overweight individuals [4]. - By 2030, medical expenses related to overweight and obesity are projected to account for approximately 22% of the total national healthcare costs [4]. - The number of patients undergoing weight loss and metabolic surgery in China has rapidly increased, with the first "ten thousand cases" achieved in three years and the second in just one year [5]. - Two main challenges in the development of weight loss and metabolic surgery in China are the need to expand quality medical resources and improve clinical specialty capabilities and safety standards [5]. Group 2: Initiatives and Recommendations - The "Blue Dragonfly" initiative was launched to promote scientific weight loss through education, hotline consultations, and assistance programs [4]. - Experts recommend a multidisciplinary approach to enhance the quality and safety of weight loss and metabolic surgery, focusing on disease-centered and weight loss-centered treatment strategies [5][8]. - There is a call for collaboration among government, health management departments, professional doctors, and patients to address weight management issues effectively [6]. Group 3: Clinical Insights and Trends - The prevalence of obesity is increasing, with over 70% of patients having a BMI over 30, and cases of severe obesity (BMI 50-60) becoming more common [7]. - There is a notable regional disparity in obesity rates, with higher rates in northern China compared to the south, and a significant gap in the availability of weight loss surgeries between coastal and inland regions [7]. - The article highlights the importance of integrating basic scientific research with industry practices, particularly in the study of gut microbiota and its relationship with obesity [9]. Group 4: Future Directions - The establishment of a comprehensive weight management system covering all age groups and medical disciplines is essential to reduce the incidence of obesity-related diseases [8]. - Recent advancements in weight loss medications have shown promising results, and there is a need for scientific and standardized use of these medications for optimal blood sugar management [8]. - The article suggests that addressing hypertension as a manifestation of obesity could provide new perspectives on obesity treatment, emphasizing lifestyle guidance and medication intervention [9].

Group 1 - Geropharm has received a compulsory license from the Russian government to produce a generic version of Ozempic (semaglutide), developed by Novo Nordisk, for diabetes treatment and weight loss [1][2] - The compulsory license allows Geropharm to manufacture its versions, Semavic and Semavic Next, starting this year without Novo Nordisk's consent [1] - The patent protection for semaglutide is valid until 2031, and Geropharm, along with another Russian pharmaceutical company Promomed, received a one-year license to produce drugs based on semaglutide at the end of 2023 [1][2] Group 2 - Since the outbreak of the Russia-Ukraine war in 2022, Western pharmaceutical companies have withdrawn from Russia, leading to a significant reduction in the availability of imported semaglutide in Russian pharmacies [2] - The Kremlin has approved a series of compulsory licenses to allow local pharmaceutical companies to use Novo Nordisk's formula without authorization, emphasizing the importance of maintaining supply for tens of thousands of type 2 diabetes patients [2] - By 2024, local companies Promomed and Geropharm are projected to capture 44% and 36% of the market share, respectively, while Novo Nordisk's share has plummeted to just 0.2% [2]

整理 | GLP1减重宝典内容团队 1月2日，礼来中国宣布，其 GLP-1 类明星药替尔泊肽注射液（商品名：穆峰达）正式在中国上市。其在首发当晚 3 秒即告售罄，足见其受追 捧程度之高。据美团显示，在首发前，该药品的预约量日环比增长高达 300%，市场对其期待值持续攀升。替尔泊肽的热度大有超越其竞争对 手司美格鲁肽的态势。 根据礼来公布的三季报， 2024年前三季度，替尔泊肽总计为礼来贡献了110亿美元的销售收入。具体来看，第三季度，降糖版替尔泊肽的销售 收入为31.13亿美元，前三季度共计收入80.1亿美元；减重版替尔泊肽第三季度销售收入则为12.58亿美元，前三季度共计收入为30.18亿美元。 ▍马斯克由司美格鲁肽换用替尔泊肽 替尔泊肽的火爆少不了名人的加持。埃隆·马斯克 (Elon Musk) 似乎在从 Ozempic 升级为一种被称为"金刚"减肥药Mounjaro的药物后，体重有 所减轻。 53 岁的马斯克在其社交媒体平台 X 上的一篇节日帖子中承认使用 Mounjaro，这是一种通常通过降低血糖水平来治疗 2 型糖尿病，以 及减重的药物。 这位亿万富翁特斯拉首席执行官发布了一张自己身穿圣诞老人服装在 ...

Core Viewpoint - Eli Lilly's experimental weight loss drug, eloralintide, shows promising results in initial studies with minimal side effects, indicating progress in the competitive weight loss treatment market [2][5]. Group 1: Drug Efficacy and Research - In a three-month trial, some participants lost over 11% of their body weight, with weight loss ranging from 2.6% to 11.3% [2][5]. - The study involved 100 participants who received different doses of eloralintide or a placebo, with gastrointestinal side effects being relatively mild [5]. - Approximately 10% of participants experienced diarrhea, and 8% reported vomiting, but detailed risk-benefit analysis by dosage was not provided [5]. Group 2: Market Context and Competition - The demand for more tolerable and convenient weight loss medications is increasing, prompting pharmaceutical companies to accelerate their efforts in this rapidly growing market [5]. - Eli Lilly's Zepbound and Novo Nordisk's Wegovy currently dominate the market, but new generation drugs are gaining attention [5]. - Roche and Zealand Pharma entered a $5.3 billion collaboration to develop petrelintide, which has shown early promise, while AbbVie has also invested in this sector [6]. Group 3: Future Developments - Eli Lilly is conducting single-agent tests of eloralintide and exploring its use in combination with Zepbound, similar to Novo Nordisk's approach with CagriSema [7]. - Eli Lilly has several promising next-generation products in late-stage development, including an oral drug named orforglipron and a more potent experimental injectable [6].

以下文章来源于体重管理三年行动 ，作者体重管理三年行动 体重管理三年行动 . 响应国家"健康中国2030"战略，落实"体重管理年"三年行动，本账号发布权威资讯 近日，"国家喊你减肥"成为网络热议焦点，卫健委主任雷海潮在两会期间的公开倡议引发广泛关注。表面上看这是一次幽默的"喊话"，但实际 上，它背后是一项关系到全民健康的重要举措。究竟是什么让国家如此关注体重问题？这场全民参与的"减重行动"将会给我们的生活带来哪些 新变化？ ▍肥胖：一场被低估的公共健康危机 1. 触目惊心的数据 令人震惊的数字显示，中国成年人超重率已高达34.3%，肥胖率达到16.4%，而青少年的肥胖问题也在持续上升。如果不采取有效措施，预计到 2030年，成年人超重和肥胖的比例或将突破70%。更值得警惕的是，肥胖与200多种疾病密切相关，包括糖尿病、心脑血管疾病和癌症等，慢 性病造成的死亡人数已超过总死亡的80%。 2. 社会和经济层面的隐形压力 肥胖不仅会缩短个人寿命，还会增加医保负担，降低整体劳动力效率。数据显示，慢性病占我国疾病总负担的七成以上，每年因肥胖相关疾病 产生的医疗费用高达数千亿元。 ▍国家亲自下场：从治病到"治未病"的转型 ...

整理 | GLP1减重宝典内容团队 替尔泊肽是一款近年来在糖尿病治疗和体重管理中备受关注的药物。 替尔泊肽通过模拟体内天然GLP-1激素的作用，帮助调节血糖水平、促进 胰岛素分泌、抑制食欲并延缓胃排空。 由于其独特的作用机制，替尔泊肽不仅在2型糖尿病治疗中表现出色，还在肥胖症的治疗中展现出巨大 潜力。 然而，并非所有患者都适合使用替尔泊肽。 本文将从适应症、禁忌症、患者特征、不良反应、未来发展方向及疗效等多个角度，全面探 讨什么样的人适合替尔泊肽。 ▍替尔泊肽的作用机制与临床优势 替尔泊肽通过激活GIP/GLP-1受体发挥作用，主要机制包括： 促进胰岛素分泌 ：替尔泊肽在血糖升高时刺激胰岛β细胞分泌胰岛素，从而降低血糖。 抑制胰高血糖素分泌 ：减少胰高血糖素的释放，进一步降低血糖水平。 延缓胃排空 ：减缓食物从胃进入小肠的速度，增加饱腹感，减少食物摄入。 抑制食欲 ：作用于中枢神经系统，减少饥饿感，有助于体重管理。 这些机制使替尔泊肽在2型糖尿病和肥胖症的治疗中具有显著优势，尤其是对于需要同时控制血糖和体重的患者。 点击关注，追踪最新GLP-1资讯 ▍替尔泊肽的主要适应症 1. 2型糖尿病患者 替尔泊肽是2型 ...

Core Viewpoint - GLP-1 (glucagon-like peptide-1) plays a crucial role in regulating blood sugar and controlling weight, with significant advancements in the development of GLP-1 drugs globally, particularly focusing on oral formulations like Rybelsus [2][4][6] Group 1: GLP-1 Overview - GLP-1 is secreted by intestinal L cells and helps in slowing gastric motility, prolonging gastric emptying time, and effectively suppressing appetite [2] - Notable GLP-1 drugs include Semaglutide (Ozempic for diabetes, Wegovy for weight loss, and Rybelsus as the first oral GLP-1 receptor agonist) and Tirzepatide (Mounjaro) [2][4] Group 2: Rybelsus Advantages - Rybelsus offers convenience as an oral medication, eliminating the need for refrigeration and improving patient adherence due to accurate dosing [4] - The formulation includes Semaglutide and an absorption enhancer (SNAC), which increases the bioavailability of the drug by approximately 100 times [4] Group 3: Clinical Research and Efficacy - The global Phase III clinical trial PIONEER involved 11,505 patients and confirmed the efficacy and safety of oral Semaglutide, showing significant reductions in blood sugar and weight [6] - In China, the HbA1c target achievement rate for newly diagnosed type 2 diabetes patients using Rybelsus monotherapy reached 92.3% [6] Group 4: Comparison of Formulations - Ozempic (injection for diabetes) and Wegovy (injection for weight loss) have similar efficacy profiles to Rybelsus, which is an oral formulation [7][8][9] - Clinical trials indicate that Rybelsus can potentially replace injection forms without dosage adjustments, providing a "pain-free" weight loss option [12] Group 5: Weight Loss Outcomes - In clinical trials, Rybelsus demonstrated significant weight loss, with a 68-week study showing an average weight reduction of 17.4% (18.34 kg) in obese patients [10] - The OASIS 4 study indicated that patients on 25 mg oral Semaglutide lost an average of 13.6% (14.4 kg) of their body weight over 64 weeks [16] Group 6: Safety and Tolerability - While oral Semaglutide shows similar efficacy to injection forms, higher doses (25 mg and 50 mg) may be required to achieve comparable weight loss results [14][15] - Safety concerns include a 14% incidence of "skin sensation abnormalities" at the 50 mg dose, which were not reported in injection forms [15]

Core Viewpoint - The article discusses the safety of GLP-1 receptor agonists (GLP-1RAs), particularly regarding their potential link to thyroid cancer, based on a recent large-scale study that provides reassuring evidence for patients and healthcare providers [1][2][3]. Group 1: Background on GLP-1RAs - GLP-1 receptor agonists, such as semaglutide and liraglutide, are gaining attention for their dual benefits of lowering blood sugar and aiding weight loss among diabetes and obesity patients [1]. - Concerns have been raised about the potential risk of thyroid cancer associated with these medications, leading to confusion among doctors and patients [2][6]. Group 2: Research Findings - A significant study published in June 2025 in the journal "Diabetes Care" analyzed data from over 460,000 type 2 diabetes patients who were first-time users of GLP-1RAs, comparing them with patients using other common second-line diabetes medications [3][7]. - The study employed rigorous methodologies, including adjustments for 90,000 variables and a one-year delay analysis to enhance the reliability of the results [7]. Group 3: Results and Implications - The study found no significant increase in thyroid cancer risk among GLP-1RA users compared to those on other medications, with the risk ratio close to 1 and not statistically significant [8]. - The incidence rate of thyroid cancer in the GLP-1RA group was approximately 0.88 to 1.03 per 1,000 person-years, comparable to the control group, indicating no elevated risk [8]. Group 4: Recommendations - The findings suggest that patients currently using or considering GLP-1RAs can be reassured about the thyroid safety of these medications [9]. - While the study has limitations, such as the exclusion of some European data and the retrospective nature of the analysis, it remains one of the most comprehensive studies on this topic to date [10][12]. Group 5: Conclusion - The research serves as an important reference for healthcare providers in making medication decisions and alleviating patient concerns regarding cancer risks associated with GLP-1RAs [11]. - Ongoing accumulation of long-term data will further enhance understanding of the safety profile of these drugs [12].

Core Viewpoint - The article emphasizes the urgent need for a comprehensive approach to weight management in China, highlighting the alarming obesity crisis and the necessity for innovative solutions that integrate technology, policy, and community efforts [3][5][18]. Group 1: Obesity Crisis and Health Implications - By 2025, the overweight rate among Chinese adults is projected to reach 34.3%, with obesity rates at 16.4%, and a 12-fold increase in youth obesity over the past 15 years [3]. - If no effective measures are taken, by 2030, adult overweight and obesity rates could soar to 70.5%, while youth rates may hit 31.8% [3]. - Obesity is linked to over 200 diseases, leading to annual medical expenditures exceeding 240 billion yuan [5]. Group 2: Comprehensive Health Ecosystem Development - The National Health Commission's "National Fitness Plan" promotes a dual focus on muscle gain and fat loss, moving away from the sole reliance on BMI for health assessments [6]. - Innovative products, such as a patented CLA+ whey protein blend, have shown promising results in trials, with users gaining an average of 2.3 kg of muscle and losing 4.7 kg of fat over three months [6]. - The "Metabolic Map" project aims to utilize wearable devices to monitor metabolic health indicators, enhancing personalized health management [7]. Group 3: New Approaches to Weight Management - Community health initiatives in regions like Guangdong and Zhejiang are incorporating gut microbiome testing into routine health checks to address obesity linked to microbiome imbalances [8]. - A combination of prebiotics and postbiotics has been developed to promote beneficial gut bacteria, resulting in users experiencing a 5 cm reduction in waist circumference and a 23% improvement in skin elasticity [8]. - The integration of skin-tightening treatments in weight loss programs is gaining traction, with high satisfaction rates reported post-treatment [9]. Group 4: Addressing Market Challenges - The weight loss market is plagued by misinformation, with 40% of products exaggerating their effectiveness, leading to consumer confusion and potential health risks [12]. - There is a significant gap in obesity treatment resources, with less than 15% of primary hospitals adhering to obesity treatment guidelines and a shortage of specialized medical professionals [13]. Group 5: Future of Weight Management - The future of weight management is expected to leverage advanced technologies such as AR body fat scanning and AI-driven personalized plans, making weight loss more intelligent and effective [17]. - A collaborative approach involving government, businesses, and communities is essential to create a supportive environment for health initiatives [17].